To Disclose or Not Disclose?
This article was originally published in RPM Report
Executive Summary
A recent Supreme Court ruling on securities act disclosure laws leaves biopharma companies in the dark about what exactly is considered “material.” Here are three principles to help sponsors stay on the right side of the law.